OverviewChartProfileKey statisticsFinancialsNews
Derivatives
TraderScreen

GILEAD SCIENCES DL-,001/  US3755581036  /

Berlin
2024-04-23  8:08:24 AM Chg. -0.03 Volume Bid3:18:27 PM Ask3:18:27 PM Market Capitalization Dividend Y. P/E Ratio
62.70EUR -0.05% 0
Turnover: 0.00		 62.69Bid Size: 240 62.93Ask Size: 240 78.3 bill.EUR - -
GlobeNewswire 04-19 ACTG Announces Launch of Clinical Trial Evaluating Combination of Three Novel Immune-based Therapies...
GlobeNewswire 04-10 Nurix Therapeutics Reports First Quarter Fiscal 2024 Financial Results and Provides a Corporate Upda...
GlobeNewswire 04-03 Opthea Appoints Sujal Shah to the Board of Directors
GlobeNewswire 04-02 Pulmonx Announces Appointment of Mehul Joshi as Chief Financial Officer
GlobeNewswire 04-02 Nurix Therapeutics Announces Extension of Strategic Collaboration with Gilead Sciences
GlobeNewswire 04-01 Xilio Therapeutics Announces Pipeline and Business Updates and Fourth Quarter and Full Year 2023 Fin...
GlobeNewswire 03-28 Assembly Biosciences Reports Fourth Quarter and Year End 2023 Financial Results and Recent Highlight...
GlobeNewswire 03-28 Xilio Therapeutics Announces $11.3 Million Private Placement Equity Financing
GlobeNewswire 03-28 Gilead and Xilio Announce Exclusive License Agreement for Tumor-Activated IL-12 Program
GlobeNewswire 03-22 HOOKIPA Pharma Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Highl...
GlobeNewswire 03-18 CIO Celebrates Innovations in Business Technology with 2024 CIO 100 & Hall of Fame Awards
GlobeNewswire 03-11 Hyku Biosciences, a Covalent Precision Medicine Company, Announces CEO Transition for its Next Phase...
GlobeNewswire 02-29 BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: CymaBay The...
GlobeNewswire 02-29 Abingworth Announces a Strategic Development Financing Agreement with Gilead Sciences; Establishes J...
GlobeNewswire 02-28 CymaBay Reports Fourth Quarter and Year Ended December 31, 2023 Financial Results and Provides Corpo...
GlobeNewswire 02-27 MAIA Biotechnology Appoints Leading Immuno-Oncology Scientist Dr. Remus Vezan as Scientific Advisor
GlobeNewswire 02-24 SHAREHOLDER UPDATE: Halper Sadeh LLC Investigates CBAY, IONM, WISH, FREE
GlobeNewswire 02-22 Press Release: Sanofi’s Board of Directors proposes the appointment of Clotilde Delbos, Anne-Françoi...
GlobeNewswire 02-17 SHAREHOLDER UPDATE: Halper Sadeh LLC Investigates DOOR, ZFOX, CBAY, WISH
GlobeNewswire 02-12 SHAREHOLDER UPDATE: Halper Sadeh LLC Investigates FANG, CBAY, WISH
GlobeNewswire 02-12 ALERT: The M&A Class Action Firm Launches Investigation of the Merger – WISH, IONM, CBAY, FANG
TeleTrader 02-12 CymaBay Therapeutics jumps 25% after Gilead deal news
GlobeNewswire 02-12 BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: CymaBay The...
TeleTrader 02-12 Gilead to buy CymaBay Therapeutics for $4.3B
GlobeNewswire 02-08 Assembly Biosciences Announces Effective Date of Reverse Stock Split